Year 2003 / Volume 95 / Number 7
Original
Immunomodulation with tacrolimus (FK 506): results of a prospective, open-label, non-controlled trial in patientswith inflammatory bowel disease

0

J. de Oca, L Vilar, J. Castellote, R. Sánchez Santos, D. Parés, S. Biondo, A. Osorio, C. del Río, J. de Oca, L Vilar, J. .Castellote, R. Sánchez Santos, D. Parés, S. Biondo, A Osorio, C. del Río,

Abstract
Tacrolimus (FK506) is widely used in the organ transplant setting, but not in the treatment of IBD.

Objective: the aim of this study was to analyse the effectiveness of tacrolimus in specific clinical presentations of inflammatory bowel disease (IBD) in which recurrence is likely.

Patients and methods: inclusion criteria were: perianal Crohn’s disease (PCD), CD in rectal stump, pouchitis and cuffitis with severely impaired function of the ileoanal pouch (IPAA), and
proven refractoriness to other therapies. Clinical assessment: Hughes’ classification (PCD); Öresland index (OI) in IPAA, endoscopy biopsy and Quality of life (QoL) using the Spanish version of the IBDQ. Response was determined as complete (CP),
partial (PR) or non-existent (NR). Tacrolimus was administered orally at a dose of 0.1 mg/kg/day (levels 5-15 µg/L).

Results: nineteen patients entered the study. Mean duration of treatment was 9.6 ± 6.3 months. In PCD, CR was reported in 66% of cases and PR in 33%, with disappearance of inflammation, stenosis and ulcers. In patients with pouchitis and cuffitis, 77% presented either CR or PR. The OI scores and QoL improved significantly after treatment (p<0.006 and p<0.002, respectively).
Adverse effects were minor and controlled by regulating the dose.

Conclusion: oral administration of tacrolimus is easy to perform and has few adverse effects when used to treat IBD in certain clinical presentations with a high likelihood of recurrence.
Share Button
New comment
Comments
No comments for this article
Related articles
Citation tools
J. de Oca, L Vilar, J. Castellote, R. Sánchez Santos, D. Parés, S. Biondo, A. Osorio, C. del Río, J. de Oca, L Vilar, J. .Castellote, R. Sánchez Santos, D. Parés, S. Biondo, A Osorio, C. del Río,. Immunomodulation with tacrolimus (FK 506): results of a prospective, open-label, non-controlled trial in patientswith inflammatory bowel disease. 0


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 227 visits.
This article has been downloaded 17 times.
Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology